1887
  1. Home
  2. A-Z Publications
  3. Avicenna
  4. Volume 2024, Issue 2
  5. Article
Volume 2024, Issue 2
  • EISSN: 2220-2749

Abstract

The objective of this study was to assess the effects of COVID-19 safety measures on outcomes in patients receiving warfarin for cardiac indications at the Heart Hospital’s anticoagulation clinic, Hamad Medical Corporation.

Two cohort surveys were studied: pre-COVID-19 (December 1, 2018, to February 28, 2019) and post-COVID-19 (April 1, 2020, to June 20, 2020). Collected data included demographics, chronic conditions, warfarin indications, clinic visits, and safety and efficacy outcomes. Thrombotic events and bleeding events were tracked in order to assess the safety of the anticoagulant clinic’s adopted procedures during the COVID-19 pandemic.

Patients who visited the clinic for 3 months before the pandemic were included in the pre-COVID-19 group, while those who visited at the peak of the pandemic in 2020 were included in the post-COVID-19 group. During the pandemic, significant reductions in thrombotic and bleeding events were noted, with a noteworthy increase in time in the therapeutic range. Notable findings included decreased ischemic strokes (13 to 1 case, -value = 0.022) and reduced major bleeding (9 to 4 cases, -value < 0.001). Time in the therapeutic range improved from 60% ± 20% to 64% ± 20% (-value < 0.001). Clinic visits decreased during the pandemic but significantly increased afterward.

COVID-19 safety measures at the anticoagulation clinic were safe and highly effective in optimizing therapy. Larger studies across multiple centers are recommended to further assess the broader safety and efficacy. The study emphasizes the ongoing need for improvements in anticoagulation management during and beyond the pandemic, potentially reshaping future care.

© 2024 The Author(s), licensee HBKU Press.
Loading

Article metrics loading...

/content/journals/10.5339/avi.2024.6
2024-12-30
2025-01-09
Loading full text...

Full text loading...

/deliver/fulltext/avi/2024/2/avi.2024.6.html?itemId=/content/journals/10.5339/avi.2024.6&mimeType=html&fmt=ahah

References

  1. Xu L, Yang S, Chen J, Shi J. The effect of COVID-19 pandemic on port performance: evidence from China. Ocean Coast Manag. 2021; 209:105660. https://www.sciencedirect.com/science/article/pii/S0964569121001447
     [Google Scholar]
  2. Abdallah I, Eltahir A, Fernyhough L, El-Bardissy A, Ahmed R, Abdulgelil M, et al.. The experience of Hamad General Hospital collaborative anticoagulation clinic in Qatar during the COVID-19 pandemic. J Thromb Thrombolysis. 2021; 52:(1):308-14. https://doi.org/10.1007/s11239-020-02276-4
     [Google Scholar]
  3. Qiu Y, Chen X, Shi W. Impacts of social and economic factors on the transmission of coronavirus disease 2019 (COVID-19) in China. J Popul Econ. 2020; 33:(4):1127-72. https://doi.org/10.1007/s00148-020-00778-2
     [Google Scholar]
  4. Fruehwirth JC, Biswas S, Perreira KM. The Covid-19 pandemic and mental health of first-year college students: examining the effect of Covid-19 stressors using longitudinal data. PLoS One. 2021; 16:(3):e0247999. https://doi.org/10.1371/journal.pone.0247999
     [Google Scholar]
  5. Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J, et al.. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus–infected pneumonia in Wuhan, China. JAMA. 2020; 323:(11):1061-9. https://doi.org/10.1001/jama.2020.1585
     [Google Scholar]
  6. Floyd CN, Ferro A. Indications for anticoagulant and antiplatelet combined therapy. BMJ. 2017; 359:j3782. . https://doi.org/10.1136/bmj.j3782
     [Google Scholar]
  7. Porter WR. Warfarin: history, tautomerism and activity. J Comput Aided Mol Des. 2010; 24:(6-7):553-73. https://doi.org/10.1007/s10822-010-9335-7
     [Google Scholar]
  8. Hirsh J, Dalen J, Anderson DR, Poller L, Bussey H, Ansell J, et al.. Oral anticoagulants: mechanism of action, clinical effectiveness, and optimal therapeutic range. Chest. 2001; 119:(1):8S-21S. https://doi.org/10.1378/chest.119.1_suppl.8s
     [Google Scholar]
  9. Holster IL, Valkhoff VE, Kuipers EJ, Tjwa ETTL. New oral anticoagulants increase risk for gastrointestinal bleeding: a systematic review and meta-analysis. Gastroenterology. 2013; 145:(1):105-12.e15. https://doi.org/10.1053/j.gastro.2013.02.041
     [Google Scholar]
  10. Nijkeuter M, Huisman MV. Pentasaccharides in the prophylaxis and treatment of venous thromboembolism: a systematic review. Curr Opin Pulm Med. 2004; 10:(5):338-44. https://doi.org/10.1097/01.mcp.0000136901.80029.37
     [Google Scholar]
  11. Decousus H, Tapson VF, Bergmann J-F, Chong BH, Froehlich JB, Kakkar AK, et al.. Factors at admission associated with bleeding risk in medical patients. Chest. 2011; 139:(1):69-79. https://doi.org/10.1378/chest.09-3081
     [Google Scholar]
  12. Ortel TL, Neumann I, Ageno W, Beyth R, Clark NP, Cuker A, et al.. American Society of Hematology 2020 guidelines for management of venous thromboembolism: treatment of deep vein thrombosis and pulmonary embolism. Blood Adv. 2020; 4:(19):4693-738. https://doi.org/10.1182/bloodadvances.2020001830
     [Google Scholar]
  13. Chai-Adisaksopha C, Crowther M, Isayama T, Lim W. The impact of bleeding complications in patients receiving target-specific oral anticoagulants: a systematic review and meta-analysis. Blood. 2014; 124:(15):2450-8. https://doi.org/10.1182/blood-2014-07-590323
     [Google Scholar]
  14. Ansell J, Hirsh J, Hylek E, Jacobson A, Crowther M, Palareti G. Pharmacology and management of the vitamin K antagonists: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest. 2008; 133:(6 Suppl):160S-98S. https://doi.org/10.1378/chest.08-0670
     [Google Scholar]
  15. Schulman S. Care of patients receiving long-term anticoagulant therapy. N Eng J Med. 2003; 349:(7):675-83. https://doi.org/10.1056/nejmcp025373
     [Google Scholar]
  16. Siegal DM, Garcia DA, Crowther MA. How I treat target-specific oral anticoagulant–associated bleeding. Blood. 2014; 123:(8):1152-8. https://doi.org/10.1182/blood-2013-09-529784
     [Google Scholar]
  17. Tomaselli GF, Mahaffey KW, Cuker A, Dobesh PP, Doherty JU, Eikelboom JW, et al.. 2017 ACC Expert Consensus decision pathway on management of bleeding in patients on oral anticoagulants. J Am Coll Cardiol. 2017; 70:(24):3042-67. https://doi.org/10.1016/j.jacc.2017.09.1085
     [Google Scholar]
  18. Davidson BL, Verheijen S, Lensing AWA, Gebel M, Brighton TA, Lyons RM, et al.. Bleeding risk of patients with acute venous thromboembolism taking nonsteroidal anti-inflammatory drugs or aspirin. JAMA Intern Med. 2014; 174:(6):947-53. https://doi.org/10.1001/jamainternmed.2014.946
     [Google Scholar]
  19. Lu C, Crowther MA, Mithoowani S. Management of intentional overdose of low-molecular-weight heparin. CMAJ. 2022; 194:(4):E122-5. https://doi.org/10.1503/cmaj.211083
     [Google Scholar]
  20. Harenberg J, Gnasso A, De Vries JX, Zimmermann R, Augustin J. Inhibition of low molecular weight heparin by protamine chloride in vivo. Thromb Res. 1985; 38:(1):11-20. https://doi.org/10.1016/0049-3848(85)90003-9
     [Google Scholar]
  21. Menéndez-Jándula B, Souto JC, Oliver A, Montserrat I, Quintana M, Gich I, et al.. Comparing self-management of oral anticoagulant therapy with clinic management. Ann Intern Med. 2005; 142:(1):1-10. https://doi.org/10.7326/0003-4819-142-1-200501040-00006
     [Google Scholar]
  22. Pell JP, McIver B, Stuart P, Malone DN, Alcock J. Comparison of anticoagulant control among patients attending general practice and a hospital anticoagulant clinic. Br J Gen Pract. 1993; 43:(369):152-4.
    [Google Scholar]
  23. Spinler SA. (2018) ’Chapter 66 - Oral Anticoagulation Therapy’, GN, Levine. Cardiology Secrets (5th Edn). Elsevier, 564-581. https://doi.org/10.1016/B978-0-323-47870-0.00066-0.
     [Google Scholar]
  24. Patel R, Czuprynska J, Roberts LN, Vadher B, Rea C, Patel R, et al.. Switching warfarin patients to a direct oral anticoagulant during the Coronavirus Disease-19 pandemic. Thromb Res. 2021; 197:192-4. https://doi.org/10.1016/j.thromres.2020.11.004
     [Google Scholar]
  25. Papala M, Gillard D, Hardman J, Romano T, Rein LE. Extending INR testing intervals in warfarin patients at a multi-center anticoagulation clinic. J Thromb Thrombolysis. 2021; 53:(3):626-32. https://doi.org/10.1007/s11239-021-02566-5
     [Google Scholar]
  26. Hecht H, Riendeau AB, Kolasinski J, Ray C, Nazeef M. Clinical impact of COVID-19 on anticoagulation management at the William S. Middleton Memorial Veterans Hospital. Blood. 2020; 136:(Suppl 1):12-3. https://doi.org/10.1182/blood-2020-141310
     [Google Scholar]
  27. Truong L, Whitfield K, Nickerson-Troy J, Francoforte K. Drive-thru anticoagulation clinic: can we supersize your care today? J Am Pharm Assoc. 2021; 61:(2):e65-7. https://doi.org/10.1016/j.japh.2020.10.016
     [Google Scholar]
  28. Kow CS, Sunter W, Bain A, Zaidi STR, Hasan SS. Management of outpatient warfarin therapy amid COVID-19 pandemic: a practical guide. Am J Cardiovasc Drugs. 2020; 20:(4):301-9. https://doi.org/10.1007/s40256-020-00415-z
     [Google Scholar]
  29. Pozzi M, Mitchell J, Henaine AM, Hanna N, Safi O, Henaine R. International normalized ratio self-testing and self-management: improving patient outcomes. Vasc Health Risk Manag. 2016; 12:387-92. https://doi.org/10.2147/vhrm.s85031
     [Google Scholar]
  30. Cope R, Fischetti B, Eladghm N, Elaskandrany M, Karam N. Outpatient management of chronic warfarin therapy at a pharmacist-run anticoagulation clinic during the COVID-19 pandemic. J Thromb Thrombolysis. 2021; 52:(3):754-8. https://doi.org/10.1007/s11239-021-02410-w
     [Google Scholar]
  31. Ammari MA, AlThiab K, AlJohani M, Sultana K, Maklhafi N, AlOnazi H, et al.. Tele-pharmacy anticoagulation clinic during COVID-19 pandemic: patient outcomes. Front Pharmacol. 2021; 12:652482. https://doi.org/10.3389/fphar.2021.652482
     [Google Scholar]
  32. Emren ZY, Şenöz O, Erseçgin A, Emren SV. Evaluation of bleeding rate and time in therapeutic range in patients using warfarin before and during the COVID-19 pandemic—warfarin treatment in COVID-19. Clin Appl Thromb Hemost. 2021; 27:107602962110214. https://doi.org/10.1177/10760296211021495
     [Google Scholar]
/content/journals/10.5339/avi.2024.6
Loading
Navigating warfarin management: Insights from the Hamad Medical Corporation during and after COVID-19
Avicenna 2024, 6 (2024); https://doi.org/10.5339/avi.2024.6
/content/journals/10.5339/avi.2024.6
/content/journals/10.5339/avi.2024.6
Loading

Data & Media loading...

  • Article Type: Research Article
Keyword(s): Anticoagulation therapy, bleeding risk, COVID-19 pandemic, DOACs, INR testing and warfarin management

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error